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Association of Carcinoma Yield with Early
Papilloma Development in SENCAR Mice
by Richard J. Bull,* Merrel Robinson,t and R. Dana Lauriet
Theresponsiveness ofSENCARmouseskinto20differentchemicalswithknowncarcinogenic properties
was assessed in initiation/promotion experiments. The purpose of these experiments was to evaluate the
extentoffalse negativeresponses in mouse skin initiation/promotion protocolsandtodetermine theextent
towhichearlypapillomadevelopmentcanbeusedtopredicttheeventualdevelopmentofmalignanttumors.
Thechemicalswereadministeredasinitiators byfourdifferentroutes: oral, intraperitoneal, subcutaneous,
andtopical. Followingthe initiating doseofcarcinogen, theanimalsweresubjectedtotopical applications
of 1 ,g 12-O-tetradecanoylphorbol-13-acetate (TPA) 3 times per week for a period of 20 weeks. The yield
ofpapillomas at 24 weeks was selected as a potential predictor ofcarcinoma yields at 52 weeks following
the start of the promotion schedule. Positive responses were observed with only eight of the compounds
tested. Where positive results were observed, there was some evidence that the response could depend both
qualitatively and quantitatively on the route of administration. However, no route was clearly superior,
i.e., different chemicals gave greater responses by different routes. Papilloma yield at 24 weeks following
the start ofthe promotion schedule was clearly related to the development ofcarcinomas at 52 weeks. No
simple linear relationship existed between papilloma yield and carcinoma development, since the number
ofmalignant tumors per papilloma decreased with increasing papilloma yields. The relationship between
papilloma and carcinoma yields appeared to be independent ofthe carcinogen used. These data indicate
that there are some limitations in using mouse skin initiation/promotion experiments as the sole basis for
identifying substances with carcinogenic activity. However, the test does perform well within certain
classes of compounds. Within the limits of these chemical classes, the use of papilloma yield to predict
carcinoma yield appearsjustified.
Introduction
There are a variety of reasons for pursuing animal
models that display a high degree ofresponsiveness to
particular stimuli. From the point of view of funda-
mental research, a strain or stock of animals that is
particularlysusceptibleto agivendiseasestateprovides
a tool for identifying some ofthe key steps involved in
the development of the disease and thus provides in-
sights into the treatment and/or prevention ofthe dis-
ease. From the context of an agency that is responsible
for ensuring that dangerous chemicals are not intro-
duced into the environment, a sensitive strain provides
the possibility of simplifying testing schemes.
Our interest in the SENCAR stock was two-fold: (1)
could the increased sensitivity ofthe skin in this stock
be used to broaden the classes ofchemical carcinogens
that could be detected and (2) could papilloma devel-
opment be used as an accurate predictor ofthe ultimate
incidence of malignant tumors? If these two questions
could be answered in the affirmative, it would allow a
much broader use ofthe skin tumorigenesis model and
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would confirm its inherent convenience as a short-term
test method in environmental carcinogenesis. Particu-
larly, we hoped that we could take advantage of the
rapid development ofpapillomas inthese mice resulting
from the initiation/promotion protocols employing 12-
O-tetradecanoylphorbol-13-acetate (TPA) as a tumor
promoter. The short time involved in the development
of these tumors and the fact that they are an easily
identifiable external lesion would make SENCAR mice
an ideal system for routine testing of tumor-initiating
agents.
ToestablishtheextenttowhichSENCARmicemight
fit this ideal, we have subjected 20 different carcino-
gens, representing 14differentchemicalclasses, totests
as tumor initiators (1). We also chose to explore the
extent to which the route of administration influences
the response to these chemicals in a classical initiation/
promotion protocol.
Materials and Methods
Chemicals
All compounds tested as initiators were purchased at
the highest purity available and submitted for analysis
by a contract laboratory, Environmental Health Re-
search and Testing, Inc. (Contract No.68-03-1720, M.BULL ET AL.
Pereira, project officer). The results of these analyses
and the source of each chemical is provided in Table 1.
Only in the case of 2-acetylaminofluorene, which was
found to be only 50% pure, does it appear that the level
of purity was so low as to make the results reported
here somewhat questionable. Since the experiment had
essentially been completed before the purity analyses
were reported, the results of tests using 2-acetylami-
nofluorene are included in this report. TPA was ob-
tained from Chemical Carcinogenesis (Eden Praire,
MN).
Animals
Female SENCAR mice were used in all experiments.
As indicated in Table 1, mice were obtained either from
Oak Ridge National Laboratories (Oak Ridge, TN), or
from Harlan Sprague-Dawley (Indianapolis, IN). Ani-
mals were begun on study when 6 to 8weeks ofage and
weremaintained onPurinarodentchow(RalstonPurina
Co., St. Louis, MO) and distilled water provided ad
libitum.
Experimental Design
Depending on the intent of the experiment, each
group ofanimals contained either40 (firstround screen-
ing), 30, or 25 mice (when multiple doses were used to
confirm positive results and to establish dose-response
relationships). Table 2 presents the doses ofeach chem-
ical that produced the largest response by each route
of exposure. The backs of the animals were shaved 3
days before application of the test chemical (tested as
initiators, only) and once weekly during the tumor pro-
motion period. Using available acute toxicity data, the
initial doses to be used in the screening phase were
selected to approximate one-fifth the LD50. Additional
doses were tested if a positive response was indicated.
On occasion, if the initial dose resulted in a marginal
response, highertotaldoseswere administered by split-
ting the initiating dose into six equal doses that were
applied over a 2-week period. Depending on the com-
pound, either acetone or ethanol was used for topical
applications and emulphor, saline or water used as the
vehicle for systemic routes of administration. Control
groups received equivalent amounts ofthe appropriate
vehicle.
Two weeks following the administration of the last
dose of the test chemical, a promotion schedule was
begun, involving the application of 1.0 jig TPA in 0.2
mL acetone to the back of each animal three times
weekly. The topical route was always used for TPA
administration regardless ofthe route by whichthe test
chemical was administered. At the highest dose ofeach
test chemical used, a group receiving acetone applica-
tions in place of TPA applications was included. These
groups were usually limited to 20 animals and served
todeterminewhetherasingledose ofthe chemicalcould
induce tumors in the absence of TPA promotion. In no
case were significant numbers of tumors observed in
Table 1. Source and analysis of carcinogen test matrix chemicals and source of SENCAR mice used to test each compound.
Compound
2-Acetylaminofluorene
Aflatoxins
Azaserine
Azobenzene
Benzo(a)pyrene
1,2-Dibromoethane
Diethylnitrosoamine
1,2-Dimethylhydrazine
1,4-Dioxane
Ethyl carbamate (urethane)
Lead acetate
3-Methylcholanthrene
Methymethanesulfonate
N-[4-(5-nitro-2-fturyl)-2-thiazoyl]-
formamide (FANFT)
2-Napthylamine
S-(2-propenyl)-1,3-benzodiazole
(Safrole)
1-Propiolactone
Source
Sigma, St. Louis, MO
Sigma
Sigma
Eastman, Rochester, NY
Sigma
Fluka, Hauppague, NY
Sigma
Aldrich, Milwaukee, WI
Aldrich
Aldrich
Fisher, Cincinnati, OH
Fluka
Aldrich
Saber Lab, Morton Grove, IL
Sigma
Aldrich
Sigma
2,4,6-Trichlorophenol Eastman
aCND = could not determine; OR = Oak Ridge National Labora
Lot # % Purity
1092-0202 50
117C-0218
72F-0401
B7A
15C-0116
171756104
49C-0348
092497
101197
JD031997
726062
66230
4120TD
791101
CND
99+
99+
99+
92
99+
98
99+
99+
99+
99+
99
99+
18C-0440-1 99
Contaminants
Carbonic acid
2-Methoxybenzoic acid
methyl ester
Triphenylmethane
Bromochloroethane
Dibromopropane
Tribromomethane
Tribromomethane
1,2,3-Trichloropropene
050197 90.2 Camphor
Cadinenes scans
109C-0516 96 2-Oxopropanoic acid
Acetic acid scans
B7B 99+
30.0%
14.0%
4.1%
5.0%
0.3%
0.3%
1.7%
SENCAR
sourcea
HSD
OR
HSD
OR
OR
HSD
OR
0.2%
HSD
HSD
OR
OR
HSD
OR
OR
HSD
0.8% HSD
4.9%
1.5% OR/HSD
2.4%
OR
= Harlan Sprague-Dawley.
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Table 2. Summary of positive and negat
carcinogens tested as tumor initiato:
SENCAR mice by different route
Compound
2-Acetylaminrofluorene
Aflatoxin B1
Azobenzene
Azaserine
Benzene
Benzo(a)pyrene
Dibromoethane
Dibutylnitrosamine
Diethylnitrosamine
Dimethylbenzan-
thracene
1,4-Dioxane
Ethyl carbamate
FANFT
Lead acetate
3-Methylcholan-
threne
Methylmethanesul-
fonate
Methylnitrosourea
3-Propiolactone
Safrole
2,4,6-Trichlorophenol
Dose producing
largest response,
mg/kg
200
1.5
200
30
200
800
50
100
500
50
200
200
400
50
0.06
5
1.3
1000
300
500
500
1000
600
250
500
40
30
100
800
470
200
NT = nottested,-- = negative, + + =
these groups. Consequently, the
from this paper to simplify preser
Tumor incidences were recorde
24 weeks following the start ofpr(
thereafter. To be included in the
tumorhad tobe atleast 1 mmindia
in the same location for three cons
weeks, the experiments were ten
icalevaluations performed forall g
noted at necropsy. Some experim4
before 52 weeks when they w
(< 0.1 tumor/animal) at all doses
Results
Table 2 summarizes the data o
all chemicals in terms ofpositive o
Chemicals werejudged positive if
nificantly different from the conc
(using amultiple cellcontingencyt
ber of animals bearing tumors, a
response of greater than 0.4 tu:
;ive results with chemical served in a group of 40 animals. A positive response
trsin the skin of female was also indicated if the tumor yield was between 0.3
!s of administration. and 0.4 tumors/animal, ifthe results were confirmed in
Route ofexposurea a separate experiment involving multiple doses, and if
Top- the results increased the statistical confidence relative
Oral IP SC ical to the first experiment. Overall, the control response
-- NT -- -- to TPA promotion in the absence of prior treatment
-- NT -- -- with a chemical was 0.08 tumor/animal (total of 50 tu-
-- NT -- -- mors in 622 animals). However, this value varied con-
-- NT ++ NT siderably between experiments and indicates the need
NT NT NT -- for caution in accepting the statistical evaluation of a
NT NT NT + + single experiment when a low-level response is ob-
NT ++ ++ NT served.
+ + NT NT NT The results in Table 2 indicate that eight of the 20
NT
NT --NT chemicalstested fortheirabilitytoinitiate skintumors NT NT NT --
-- NT -- NT in SENCAR mice were found to be positive by one or
NT NT NT -- more routes ofadministration. Six ofthe eight positive
-- NT -- -- compounds were found to initiate tumors when applied
NT NT NT + + topically, the usual route of administration. Seven of
+ + NT NT NT the eight compounds were positive by the subcutaneous
NT ++ ++ NT route (administered in the back), and five of the eight
-- NT -- -- were positive if the chemical was administered orally.
NT + + NT NT When administered orally, the three polycyclic aro-
+ + NT + + + + matic hydrocarbons, i.e., (PAHs) [7,12-dimethyl-
NT NT ++ NT benz(a)anthracene, (DMBA), benzo(a)pyrene [B(a)P],
-- NT NT -- and3-methylcholanthrene(MCA), ethylcarbamate, and
+ + NT + + NT methylnitrosourea were positive. The topical route of
NT NT NT + + exposure added a-propiolactone to the list of positive
-- NT -- compounds. This was the only route by which ,B-pro- piolactone produced a significant response. N-[4-(5-Ni-
++ + + + + ++ tro-2-furyl)thiazolyl]formamide (FANFT) and azaser-
-- NT NT +_ ine were positive only if administered subcutaneously.
NT N-- -- Testing by the intraperitoneal route was limited to a
few compounds, and there were nouniquelypositive or
-positive, +- = equivocal, negative compounds identified by this route.
Figure 1 provides the dose-response information ob-
tained for the eight positive compounds. The route-spe-
results were omitted cificnatureoftheresponseswasnotentirelyqualitative,
ntation. since rather marked differences in potency were ob-
d weekly for the first served using different routes of administration of the
)motion, and monthly same chemical. PAHs, in particular, are very much
cumulative count, a more potent when they are topically applied relative to
Lmeterandbepresent systemic routes ofadministration (Figs. le, lf, and lg).
;ecutive weeks. At 52 In general, the activity observed with PAHs by this
minated and histolog- route was at least two orders ofmagnitude greaterthan
rosslesionsthat were the alternate routes. On the other hand, ethyl carba-
ents were terminated mate was approximately two times as potent in initi-
ere clearly negative ating skin tumors by systemic routes ofadministration
tested at 24 weeks. as by topical application. The basis forthese differences
was not clear but may be related to the way in which
the activated form of the chemical reached its critical
site of action.
btained from tests of In general, responses were observed to increase with
rnegative responses. dose of the initiating agent. This observation was par-
the response was sig- ticularly apparent with the PAHs, in which the multi-
urrent control group plicity of tumors continued to increase to 10 or more
;estbased onthe num- tumors/animal as the dose was increased. At that point,
it p < 0.01) and if a a decreased response was noted with DMBA. This de-
mors/animal was ob- crease may be more apparent than real because of the
difficulty of accurately scoring tumors as they exceed
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FIGURE 1. Dose-response relationships ofchemicals that were found to be positive as tumor initiators in the skin offemale SENCAR mice.
Data plotted is given as tumors per animal and represents the cumulative papilloma yield observed 24 weeks after beginning the tumor
promotion schedule with TPA: (A) 3-propiolactone, (B) ethyl carbamate, (C) FANFT, (D) methylnitrosourea, (E) B(a)P, (F) dimethyl-
benzanthracene, (G) 3-methyleholanthrene, (H) azaserine. Route of administration of chemicals were: oral (A), topical (CO), subcutaneous
(0), and intraperitioneal (0).
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this number. On the other hand, the response to f-
propiolactone leveled offand even decreased slightly as
the tumor yield began to exceed three tumors/animal.
This finding apparently reflected areal maximum in the
response to B-propiolactone, since an increase in mor-
tality was not observed at the highest dose tested. Sim-
ilar types of maxima have been observed with other
direct-acting initiators (2). The limitation on the re-
sponse to FANFTappears tobemuchmore severethan
that observed with the other agents. Responses ofsim-
ilar magnitude were seen with subcutaneous adminis-
tration of FANFT in other experiments, and the data
have repeatedly met our criteria for statistical signifi-
cance. It is perhaps notable that FANFT was clearly
negative by all other routes of administration. There-
fore, the possibility that this response was secondary
to local irritation produced by FANFT cannot be ex-
cluded. Another possible explanation is that the capac-
ity for local metabolism ofFANFT is limited: systemic
metabolism may have produced metabolites that were
not active in the skin. The only other compound that
was positive by the subcutaneous route alone, azaser-
ine, produced a much less equivocal result and did not
appear to be self-limiting.
The relationship between papilloma development at
24 weeks after the start of the promotion schedule (or
4 weeks following its termination) and the incidence of
carcinomas observed in animals maintained on studyfor
a full year is plotted in Figure 2A. Twenty-four weeks
was chosen for this parameter because statistical eval-
uations in prior studies indicated that it was optimal for
papilloma yields using weakly active compounds. Later
times were found to decrease the statistical confidence
of the data (3). Although the probability of carcinoma
0.60-
(6) 0.45-
:
o 0.30-
L
m 0.15.
n
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development increases as papillomas yield increases, it
was clear that there is no simple linear relationship
between the development of benign and malignant tu-
mors. Only data obtained from groups that averaged
fewer than 14 papillomas/animal were included in the
figure to minimize the problem ofscoring coalesced tu-
mors. Another reason for limiting the results to a max-
imum response was that the yield of carcinomas at 52
weeks per papilloma at 24 weeks approximated 0.1.
Higher doses resulted in earlier development of fatal
malignant tumors. These early deaths obviously distort
any simple relationship between the two tumor types
atthesetwotimeintervals. Anadditionalconcernabout
therelationshipbetweencarcinomadevelopmentversus
early papilloma yield was that the upperportions ofthe
curve (i.e., greaterthan twopapillomas/animal) is dom-
inated by data from PAHs; no other chemical produced
an average tumor yield greater than four papillomas/
animal. Consequently, the PAH data and the nonPAH
data have been segregated in panels B and C ofFigure
2. The curve has also been confined to tumor yields of
less than four tumors/animal to allow a better compar-
ison of the relationship at these lower tumor yields.
There are no obvious differences in the relationship be-
tween papillomas and carcinomas whether they are in-
duced by PAH or non-PAH carcinogens.
In Table 3 the control animals for those experiments
that involved topical applications of the chemicals can
becompared acrossindividualexperiments. Inaddition,
thereproducibility oftheresponses offemale SENCAR
mice to identical doses ofbenzo(a)pyrene administered
as the positive control in a variety ofotherexperiments
is also presented. All these animals were subjected to
the TPA promotion schedule. It is apparent from these
B
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FIGURE 2. Relationship between papilloma yield at 24 weeks following the beginning of the tumor promotion schedule and the carcinoma
yield by 52 weeks. (A) all the data from experiments that were maintained for the 52-week time period; (B,C) expanded scale comparison
of this relationship with B(a)P (B) and non-PAH initiators (C).
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Table 3. Reproducibility of tumor yields in control and
benzo(a)pyrene-initiated mice following TPA promotion.
Trial Sum
Treatment 1 2 3 4 5 6 7 (Avg)
Benzo(a)pyrenea
N 29 29 15 29 30 132
Papillomas/mouseb 3.48 4.44 1.73 0.72 2.10 (2.58)
Carcinomas/mousec 0.27 0.37 0.20 0.07 0.07 (0.22)
Carcinomas/papillomas 0.07 0.09 0.12 0.10 0.08 (0.085)
Acetone
N 29 40 40 40 40 30 24 243
Papillomas/mouse 0.14 0.08 0.23 0.45 0.03 0.03 0.00 (0.15)
aBenzo(a)pyrene was administered topically at a dose of 1 mg/kg
body weight. In all cases, 1 jig TPA was applied topically in 0.2 mL
acetone 3 times weekly beginning 2 weeks after the initiating dose
and continued for 20 additional weeks.
bPapillomas/mouse = numbers ofpapillomas/mouse 24 weeks after
beginning promotion.
cCarcinomas/mouse = number ofcarcinomas/mouse 52 weeks after
beginning promotion.
data that there is considerable variability in the re-
sponse of SENCAR mice to a constant dose of B(a)P.
However, the relationship between cumulative papil-
loma yield at 24 weeks and carcinoma development at
1 year remained within fairly narrow limits (i.e., a ratio
of 0.07 to 0.12 carcinomas/papilloma) despite a 6-fold
variation in the papilloma yield. Similar variation in
response was observed in the papilloma yield in animals
that received only TPA promotion (except for the ap-
plication of the vehicle). In this case, the control inci-
dence ofpapillomas varied from zero to as high as 0.45/
animal. Admittedly, the 0.45 value is very rarely en-
countered (this was only the second time in more than
100 experiments in our experience). However, it does
point out the difficulty in accepting marginal responses
as significant (e.g., our results with FANFT) without
confirmation in separate experiments.
Conclusions
The present study was undertaken as part ofa larger
effort directed at the question of whether a group of
short-term in vivo carcinogenesis assays might allow
some estimation of carcinogenic hazards without re-
sortingto lifetime feeding studies (1). Such an approach
had been previously suggested by Weisburger and Wil-
liams (4). The major reason for choosing multiple tests
was that a cursory examination of the literature ap-
peared to indicate that individual test systems based on
the responses of a single target organ had relatively
high rates of false negative responses. This was defi-
nitely the case with the mouse skin initiation-promotion
protocols that have used strains of mice less sensitive
to tumor initiation than the SENCAR stock (5) .
Chemicals used to evaluate the various test systems
(1) were deliberately chosen to represent awide variety
of chemical classes and to affect a variety oftarget or-
gans. In some respects, the chemicals selected provided
an overly rigorous test of each system's ability to re-
spond. For example, although benzene has been rec-
ognized as a human carcinogen for years, it has been
very difficult to induce tumors in experimental animals
with this chemical. Similarly, the carcinogenic activity
of1,4-dioxane is very low, and questions concerning the
mechanismbywhichlead acetateproduces renaltumors
pose some difficulties. However, it was felt as a first
approximation that the definition of carcinogenic activ-
ity must simply refer to the ability to increase tumor
incidence in lifetime studies with noregard forpotential
differences in mechanism.
Despite the above reservations, it was clear that the
rate of false negative responses to chemicals with rec-
ognized carcinogenic activity is quite high when they
are tested as tumor initiators in the mouse skin. There
can be no doubt about the carcinogenic activity asso-
ciated with 2-acetylaminofluorene, aflatoxin B1, azoben-
zene, dibromoethane, dibutylnitrosamine, and diethyl-
nitrosamine. Overall, the false negative rate was 60%.
These results do not argue that the mouse skin ini-
tiation/promotion assay is without value in evaluating
carcinogenic activity of various chemicals. This system
appears to be well adapted to the detection ofa variety
ofdirect-acting carcinogens (2,3). It has been routinely
used to assay the carcinogenic potency ofPAHs (6) and
has been useful in detecting the carcinogenic activity of
chemicals possibly related to ethyl carbamate in terms
of their mechanism of action, such as vinyl carbamate
and acrylamide (3).
The present results suggest that the development of
papillomas was predictive of the later development of
carcinomas. This finding is in essential agreement with
the data reviewed by Burns et al. (7), which indicated
a 5 to 7% conversion of papillomas to carcinomas. To
the extent that it could be ascertained, this relationship
did not appear to depend on the individual chemical.
There was as much scatter in the relationship when a
single chemical was involved (B[a]P) in multiple tests
(Fig. 2B) as when a variety ofchemicals were involved
in the tests (Fig. 2C). It should be noted, however, that
no simple linear relationship exists between the devel-
opment of papillomas at 24 weeks and carcinoma inci-
dence at 52 weeks. It was clear that circumstances in-
volving low papilloma yields (including animals that
received only TPA treatments) had a higher likelihood
of yielding carcinomas relative to the papilloma yield
than when high papilloma yields were involved. One
must be cautious in interpreting these data because the
lethality ofmalignant tumors biases the results at high
papillomayields. Nevertheless this curvilinear relation-
ship appears to be present in papilloma yields where
survival was not limiting (i.e., < 4 papillomas/animal).
The research performed in this paper has been peer and adminis-
trativelyreviewed bythe U.S. Environmental Protection Agency and
approved forpublication. Mention oftrade names orcommercialprod-
ucts does not constitute endorsement or recommendation for use.
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